J 2020

Nonalcoholic Fatty Pancreas Disease: Clinical Consequences

DITE, Petr, Martin BLAHO, Martina BOJKOVA, Petr JABANDŽIEV, Lumír KUNOVSKÝ et. al.

Basic information

Original name

Nonalcoholic Fatty Pancreas Disease: Clinical Consequences

Authors

DITE, Petr (203 Czech Republic), Martin BLAHO (203 Czech Republic), Martina BOJKOVA (203 Czech Republic), Petr JABANDŽIEV (203 Czech Republic, belonging to the institution) and Lumír KUNOVSKÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Digestive Diseases, BASEL, KARGER, 2020, 0257-2753

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.404

RIV identification code

RIV/00216224:14110/20:00115602

Organization unit

Faculty of Medicine

DOI

UT WoS

000522852200011

Keywords in English

Pancreas steatosis; Nonalcoholic fatty pancreas disease; Nonalcoholic steatopancreatitis; Metabolic syndrome; Cardiovascular diseases; Diabetes mellitus; Obesity; Pancreatic carcinoma; Exocrine pancreatic insufficiency

Tags

Tags

International impact, Reviewed
Změněno: 7/5/2020 09:02, Mgr. Tereza Miškechová

Abstract

V originále

Metabolic syndrome and its components such as obesity, hypertriglyceridemia, type-2 diabetes mellitus (DM-T2), and arterial hypertension are unequivocally serious problems for every society. This is especially true in economically developed countries where the imbalance in lifestyle between caloric intake and caloric output still gets greater and greater. This fact is not only a concern for the adult population but for children as well. However, metabolic syndrome does not only affect society and health in regards to cardiovascular diseases, it significantly concerns gastroenterology where it is classified as nonalcoholic fatty pancreas disease (NAFPD). The data gained from several trials show that the prevalence of NAFDP is 33% (95% CI 24-41%). When it comes to the diagnostic procedures concerning the presence of pancreatic fat, a whole spectrum of suitable methods are recommended. Probably, the most exact method is the use of magnetic resonance imaging. However, for common clinical practice, the abdominal sonographic examination based on the comparison of the pancreatic parenchymatous echogenity versus renal or hepatic echogenity is used. The clinical consequences of pancreatic steatosis and steatopancreatitis are significant. These diseases are connected with DM-T2 and insulin resistance. In recent years, changes of exocrine pancreatic function, particularly its decrease, have also been described. It is known that there is a close correlation between NAFPD and nonalcoholic hepatic steatosis and also with the increased thickness of aortic intima-media. There is also an important relationship between NAFPD and pancreatic carcinoma. Pancreatic steatosis, and especially its NAFPD form, is a serious state which can be treatable by the possible effective management of metabolic syndrome parameters, including obesity.